Inflammatory manifestations of HTLV-1 and their therapeutic options
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Human T lymphotropic virus type 1 (HTLV-1) is one of the most intriguing retroviruses infecting humans. Most commonly, infection remains undetected, since it does not cause obvious harm, yet in 4-9% of patients, this infection can be devastating, causing adult T-cell leukemia/lymphoma and/or HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). This review concentrates on all inflammatory aspects of HTLV-1 infection: HAM/TSP, HTLV-1 associated uveitis, HTLV-1 associated conjunctivitis, sicca syndrome and interstitial keratitis, HTLV-1 associated Sjögren's syndrome, Hashimoto's thyroiditis and Graves' disease, HTLV-1 associated pulmonary disease, infective dermatitis associated with HTLV-1, HTLV-1 associated inflammatory myositis and HTLV-1 associated arthritis. With the exception of HAM/TSP treatment, studies of these conditions are sparse and even for HAM/TSP, the level of evidence is limited. While control or elimination of infection remains a goal, most therapy beyond symptomatic management is directed at the immune response to HTLV-1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428 · cited 2×
“Epidemiology of HTLV-1 infection It has been estimated that 10–20 million people are infected with HTLV-1 worldwide [19,20].”
BackgroundSpread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the Cytoskeleton
Igakura, T., Stinchcombe, J. C., Goon, P. K. C., Taylor, G. P., Weber, J. N., Griffiths, G. M., Tanaka, Y., Osame, M., & Bangham, C. R. M. (2003) · Science · doi:10.1126/science.1080115 · Cited by 755
Self-citationNagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694
Infective dermatitis of Jamaican children: a marker for HTLV-I infection
Blattner, W., LaGrenade, L., Hanchard, B., Fletcher, V., & Cranston, B. (1990) · The Lancet · doi:10.1016/0140-6736(90)92896-p · Cited by 453
Jeffery, K. J. M., Usuku, K., Hall, S. E., Matsumoto, W., Taylor, G. P., Procter, J., Bunce, M., Ogg, G. S., Welsh, K. I., Weber, J. N., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3848 · Cited by 419
Self-citationPais-Correia, A.-M., Sachse, M., Guadagnini, S., Robbiati, V., Lasserre, R., Gessain, A., Gout, O., Alcover, A., & Thoulouze, M.-I. (2010) · Nature Medicine · doi:10.1038/nm.2065 · Cited by 344 · cited 1×
“cell-to-cell transmission of HTLV-1 occurs in vivo remains unclear, but extracellular viral assemblies in biofilms [17] and formation of a tight virological synapses [18] have been observed ex vivo.”
BackgroundHuman T-Lymphotropic Virus Type I (HTLV-I) Seroprevalence in Jamaica
Murphy, E., Figueroa, P., Gibbs, W. N., Holding-Cobham, M., Cranston, B., Malley, K., Bodner, A. J., Alexander, S. S., & Blattner, W. A. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115824 · Cited by 199
Saito, M., Matsuzaki, T., Satou, Y., Yasunaga, J.-I., Saito, K., Arimura, K., Matsuoka, M., & Ohara, Y. (2009) · Retrovirology · doi:10.1186/1742-4690-6-19 · Cited by 184 · cited 1×
“• High HTLV-1 Tax protein expression and low cytotoxic T lymphocyte (CTL) lysis [67], IL-2-secreting Tax-specific CD8 T cells and IFN-g-secreting Tax-specific CD4 T cells [68], positive HTLV-1 HBZ protein expression [69] and low HBZ affinity of CD8 T-cell response are directly HTLV-1: Outcome of infection”
BackgroundIzumo, S., Goto, I., Itoyama, Y., Okajima, T., Watanabe, S., Kuroda, Y., Araki, S., Mori, M., Nagataki, M., Matsukura, S., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.1016 · Cited by 164 · cited 2×
“To date, therapeutics in HAM/TSP include: antiretrovirals [109], corticosteroids [110,111], steroid-sparing immunosuppressive drugs such as azathioprine [110], methotrexate [112], ciclosporin-A [113], monoclonal antibodies [114], interferons [110,115] and histone de-acetylase inhibitors [116,117].”
BackgroundTherapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Cited by
Schierhout, G., McGregor, S., Gessain, A., Einsiedel, L., Martinello, M., & Kaldor, J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30402-5 · Cited by 250
Reducing the global burden of HTLV-1 infection: An agenda for research and action
Willems, L., Hasegawa, H., Accolla, R., Bangham, C., Bazarbachi, A., Bertazzoni, U., Carneiro-Proietti, A. B. D. F., Cheng, H., Chieco-Bianchi, L., Ciminale, V., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.10.015 · Cited by 140
Self-citationAfonso, P. V., Cassar, O., & Gessain, A. (2019) · Retrovirology · doi:10.1186/s12977-019-0504-z · Cited by 90
Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019
Araujo, A., Bangham, C. R. M., Casseb, J., Gotuzzo, E., Jacobson, S., Martin, F., Penalva de Oliveira, A., Puccioni-Sohler, M., Taylor, G. P., & Yamano, Y. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000832 · Cited by 87
“47% over a median of 3 years in 1 cohort.(2,3)”
BackgroundSelf-citationEinsiedel, L., Chiong, F., Jersmann, H., & Taylor, G. P. (2021) · Retrovirology · doi:10.1186/s12977-020-00543-z · Cited by 43
Self-citation
Metadata
- Authors
- Martin, F., Taylor, G. P., & Jacobson, S.
- Venue
- Expert Review of Clinical Immunology
- Publisher
- Informa UK Limited
- Published
- 2014-10-23
- Volume
- 10
- Issue
- 11
- Pages
- 1531-1546
- ISSN
- 1744-666X (ISSN-L)
- 1744-8409
- OpenAlex
- W2139475271
- Cited by
- 147
- References
- 26
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory manifestations of HTLV-1 and their therapeutic options. https://app.cochat.ai/papers/10.1586/1744666x.2014.966690
- The paper
- Martin, F., Taylor, G. P., & Jacobson, S. (2014). Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Review of Clinical Immunology. https://doi.org/10.1586/1744666x.2014.966690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.